International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 29-35 , 1 September 2009

Dose–Volume Relationships for Acute Bowel Toxicity in Patients Treated With Pelvic Nodal Irradiation for Prostate Cancer

  • Claudio Fiorino, Ph.D.

      Affiliations

    • Department of Medical Physics, San Raffaele Scientific Institute, Milan, Italy
    • Corresponding Author InformationReprint requests to: Claudio Fiorino, Ph.D., Medical Physics, Scientific Institute San Raffaele, via Olgettina 60, 20132 Milan. Tel: (+39) 02-26432278; Fax: (+39) 02-26432773
    • ,
  • Filippo Alongi, M.D.

      Affiliations

    • Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy
    • Istituto di Bioimaging e Fisiologia Molecolare–Consiglio Nazionale delle Ricerche, Unità Operativa Supporto, Cefalù, Italy
    • ,
  • Lucia Perna, Ph.D.

      Affiliations

    • Department of Medical Physics, San Raffaele Scientific Institute, Milan, Italy
    • ,
  • Sara Broggi, Ph.D.

      Affiliations

    • Department of Medical Physics, San Raffaele Scientific Institute, Milan, Italy
    • ,
  • Giovanni Mauro Cattaneo, Ph.D.

      Affiliations

    • Department of Medical Physics, San Raffaele Scientific Institute, Milan, Italy
    • ,
  • Cesare Cozzarini, M.D.

      Affiliations

    • Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy
    • ,
  • Nadia Di Muzio, M.D.

      Affiliations

    • Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy
    • ,
  • Ferruccio Fazio, Prof, M.D.

      Affiliations

    • Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy
    • ,
  • Riccardo Calandrino, Ph.D.

      Affiliations

    • Department of Medical Physics, San Raffaele Scientific Institute, Milan, Italy

Received 11 July 2008 ,Revised 28 October 2008 ,Accepted 29 October 2008.

References 

  1. Dirix P, Haustermans K, Junius S, et al. The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol. 2006;79:1–14
  2. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  3. Roach M, DeSilvio M, Valicenti R, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006;66:647–653
  4. Ashman JB, Zelefsky MJ, Hunt MS, et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:765–771
  5. Cavey ML, Bayouth JE, Colman M, et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol. 2005;181:431–441
  6. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2004;59:267–284
  7. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:649–656
  8. Price RAJ, Hannoun-Levi JM, Horwitz E, et al. Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:583–592
  9. Sanguineti G, Cavey ML, Endres EJ, et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?. Strahlenther Onkol. 2006;182:543–549
  10. Sanguineti G, Cavey ML, Endres EJ, et al. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?. Int J Radiat Oncol Biol Phys. 2006;64:151–160
  11. Vaarkamp J, Adams EJ, Warrington AP, Dearnaley DP. A comparison of forward and inverse planned conformal, multi segment and intensity modulated radiotherapy for the treatment of prostate and pelvic nodes. Radiother Oncol. 2004;73:65–72
  12. Wang-Chesebro A, Xia P, Coleman J, et al. Intensity-modulated radiotherapy improves lymphnode coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:654–662
  13. Liu YM, Shiau CY, Lee ML, et al. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical sparing in prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1113–1123
  14. Hong TS, Tomè WA, Jaradat H, et al. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Acta Oncol. 2006;45:717–727
  15. Adams EJ, Convery DJ, Cosgrove VP, et al. Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement. Radiother Oncol. 2004;70:1–10
  16. Cozzarini C, Fiorino C, Di Muzio N, et al. Significant reduction of acute toxicity following pelvic irradiation with Helical TomoTherapy in patients with localized prostate cancer. Radiother Oncol. 2007;84:164–170
  17. Arcangeli S, Saracino B, Petrongari MG, et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous. Radiother Oncol. 2007;84:148–155
  18. Muren LP, Wasbo E, Helle SI, et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences. Int J Radiat Oncol Biol Phys. 2008;71:1034–1041
  19. Sanguineti G, Endres EJ, Parker BC, et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol. 2008;47:301–310
  20. Letschert JG, Lebesque JV, Aleman BM, et al. The volume effect in radiation-related late small bowel complications: Results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol. 1994;32:116–123
  21. Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol. 1995;13:1409–1416
  22. Baglan KL, Frazier RC, Yan D, et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2002;52:176–183
  23. Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2003;69:201–207
  24. Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose–volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys. 2006;66:505–513
  25. Huang EY, Sung CC, Ko SF, et al. The different volume effects of small-bowel toxicity during pelvic irradiation between gynaecological patients with and without abdominal surgery: A prospective study with computed-tomography-based dosimetry. Int J Radiat Oncol Biol Phys. 2007;69:732–739
  26. Robertson JM, Lockman D, Yan D, Wallace M. Te dose-volume relationships of small bowel irradiation and acute Grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:413–418
  27. Martinez-Monge R, Fernandes PS, et al. Cross-sectional nodal atlas: A tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology. 1999;211:815–828
  28. Mackie TR, Kapatoes J, Ruchala K, et al. Image guidance for precise conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:89–105
  29. Mackie TR, Holmes T, Swerdloff S, et al. Tomotherapy: A new concept for the delivery of dynamic conformal radiotherapy. Med Phys. 1993;20:1709–1719
  30. Fiorino C, Dell'Oca I, Pierelli A, et al. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol. 2006;78:276–282
  31. Grigorov G, Kron T, Wong E, et al. Optimization of Helical Tomotherapy treatment plans for prostate cancer. Phys Med Biol. 2003;48:1933–1943
  32. Shepard DM, Olivera GH, Reckwerdt PJ, Mackie TR. Iterative approaches to dose optimization in tomotherapy. Phys Med Biol. 2000;45:69–90
  33. Fokdal L, Honore H, Hoyer M, von der M. Dose–volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol. 2005;74:203–210
  34. Hysing LB, Kvinnsland Y, Lord H, Muren LP. Planning organ at risk volume margins for organ motion of the intestine. Radiother Oncol. 2006;80:349–354
  35. Sanguineti G, Little M, Endres EJ, et al. Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. Radiother Oncol. 2008;88:95–101
  36. Kvinnsland Y, Muren LP. The impact of organ motion on intestine doses and complication probabilities in radiotherapy of bladder cancer. Radiother Oncol. 2005;76:43–47
  37. Hysing LB, Skorpen TN, Alber M, et al. Influence of organ motion of conformal vs intensity-modulated pelvic radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:1496–1503
  38. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose–volume constraints in high-dose conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:953–962
  39. Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3DCRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1130–1137
  40. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  41. Peeters STH, Hoogeman M, Heemsbergen WD, et al. Rectal bleeding, fecal incontinence and high stool frequency after conformal radiotherapy for prostate cancer: Normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys. 2006;66:11–19
  42. Fonteyne V, De Neve W, Villeirs G, et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol. 2007;84:156–163
  43. Smit WG, Pa Helle, van Putten WL, et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18:23–29

 Conflicts of interest: none.

PII: S0360-3016(09)00087-X

doi: 10.1016/j.ijrobp.2008.10.086

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 29-35 , 1 September 2009

Article Tools

* Image Usage & Resolution